Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Researchers sought to determine whether detection of FLT3 internal tandem duplications would be prognostic of risk of relapse and death in AML.
The approval was based on data from the phase 3 AGILE trial.
Although mortality-to-incidence indices are improving globally, the increasing burden of AML is “concerning,” according to researchers.